Citations

Clear

959 citation(s) found for "Service, F J".

A single injection of kisspeptin‐54 temporarily increases luteinizing hormone pulsatility in healthy women
Jayasena, Channa , Comninos, Alexander , Veldhuis, Johannes D. , Abbara, Ali , Izzi‐Engbeaya, Chioma , Donaldson, Mandy, Ghatei, Mohammad A., Bloom, Stephen R. , Dhillo, Waljit S. , Misra, Shivani , Jayasena, Channa N

Mayo Clinic

Clinical Endocrinology | March 2, 2013 | Volume: 79 | Issue: 4 | Pages: 558-563

10.1111/cen.12179 | PMID 23452073 Get It

SummaryBackgroundKisspeptin is a novel hypothalamic peptide which stimulates endogenous gonadotrophin releasing hormone (GnRH) secretion. A single subcutaneous bolus injection of kisspeptin‐54 increases circulating luteinizing hormone (LH) levels in women, but its acute effects on LH pulsatility are not known.AimsTo investigate the effects of a single subcutaneous (sc) injection of kisspeptin‐54 administration on LH pulsatility in healthy female volunteers.MethodsSix healthy female adult volunteers underwent 10‐minute blood sampling for serum LH measurement for 8 h during the follicular phase of menstrual cycle. Sc bolus injection of saline or kisspeptin‐54 (0·15, 0·30 or 0·60 nmol/kg) was administered 4 h after commencing the study. A previously described, blinded deconvolution method was used to detect LH pulses.ResultsMean number of LH pulses was increased significantly following 0·30 and 0·60 nmol/kg kisspeptin‐54 when compared with saline (mean increase in number of LH pulses per 4 h, following injection: −0·17 ± 0·54, saline; +2·33 ± 0·56, 0·30 nmol/kg kisspeptin‐54, P < 0·05 vs saline; +2·33 ± 0·80, 0·60 nmol/kg kisspeptin‐54, P < 0·05 vs saline). LH pulse secretory mass increased following injection of 0·60 nmol/kg in five of six subjects, but the mean change in all subjects was non‐significant when compared with saline (mean increase in pulse secretory mass in IU/l following injection: +0·35 ± 0·40, saline; +2·61 ± 1·17, 0·60 nmol/kg kisspeptin‐54, P = 0·10 vs saline).ConclusionsA single injection of kisspeptin‐54 temporarily stimulates the number of LH pulses in healthy women. Further studies are required to investigate the therapeutic potential of kisspeptin‐54 injection to restore LH pulsatility in patients with reproductive disorders caused by impaired GnRH secretion.
Preoperative Detection of Pancreatic Insulinomas on Multiphasic Helical CT
Fidler, Jeff L. , Reading, Carl C., Andrews, James C. , Thompson, Geoffrey B. , Grant, Clive S., Service, F. John, Fidler, Jeff L. , Fletcher, Joel G.

Mayo Clinic

American Journal of Roentgenology | February 28, 2013 | Volume: 181 | Issue: 3 | Pages: 775-780

10.2214/ajr.181.3.1810775 | PMID 12933480 Get It

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
Pardanani, Animesh , Akin, Cem , Reiter, Andreas , George, Tracy I. , Hermine, Olivier , Kluin‐Nelemans, Hanneke C. , Hartmann, Karin , Sperr, Wolfgang R. , Schwartz, Lawrence B. , Arock, Michel , Sotlar, Karl , Horny, Hans-Peter, Metcalfe, Dean D. , Escribano, Luís, Verstovšek, Srđan , Tefferi, Ayalew , Valent, Peter , Gotlib, Jason , Brockow, Knut , Órfão, Alberto , DeAngelo, Daniel J. , Verstovsek, Srdan , George, Tracy I , Sperr, Wolfgang , Valent, Peter , Hermine, Olivier , Akin, Cem , Arock, Michel , Kluin-Nelemans, Hanneke C

Mayo Clinic

Blood | January 17, 2013 | Volume: 121 | Issue: 13 | Pages: 2393-2401

10.1182/blood-2012-09-458521 | PMID 23325841 Get It

Abstract Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.
A KCNQ1 Mutation Causes a High Penetrance for Familial Atrial Fibrillation
Bartos, Daniel C. , Anderson, Jeffrey , Bastiaenen, Rachel , Johnson, Jonathan N. , Gollob, Michael H. , Tester, David J. , Burgess, Don E. , Homfray, Tessa , Behr, Elijah R. , Ackerman, Michael J. , Guicheney, Pascale , Delisle, Brian P. , Behr, Elijah Raphael , Gollob, Michael H

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 11, 2012 | Volume: 24 | Issue: 5 | Pages: 562-569

10.1111/jce.12068 | PMID 23350853 Get It

R231H Causes a High Penetrance for Familial AFBackgroundAtrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence is expected to grow. A genetic predisposition for AF has long been recognized, but its manifestation in these patients likely involves a combination of rare and common genetic variants. Identifying genetic variants that associate with a high penetrance for AF would represent a significant breakthrough for understanding the mechanisms that associate with disease.Method and ResultsCandidate gene sequencing in 5 unrelated families with familial AF identified the KCNQ1 missense mutation p.Arg231His (R231H). In addition to AF, several of the family members have abnormal QTc intervals, syncope or experienced sudden cardiac arrest or death. KCNQ1 encodes the voltage‐gated K+ channel that conducts the slowly activating delayed rectifier K+ current in the heart. Functional and computational analyses suggested that R231H increases KCNQ1 current (IKCNQ1) to shorten the atrial action potential (AP) duration. R231H is predicted to minimally affect ventricular excitability, but it prevented the increase in IKCNQ1 following PKA activation. The unique properties of R231H appeared to be caused by a loss in voltage‐dependent gating.ConclusionsThe R231H variant causes a high penetrance for interfamilial early‐onset AF. Our study indicates R231H likely shortens atrial refractoriness to promote a substrate for reentry. Additionally, R231H might cause abnormal ventricular repolarization by disrupting PKA activation of IKCNQ1. We conclude genetic variants, which increase IKs during the atrial AP, decrease the atrial AP duration, and/or shorten atrial refractoriness, present a high risk for interfamilial AF.
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Palladini, Giovanni , Dispenzieri, Angela , Kumar, Shaji , Wechalekar, Ashutosh , Hawkins, Philip N. , Schönland, Stefan , Comenzo, Raymond L. , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Jaccard, Arnaud , Klersy, Catherine , Merlini, Giampaolo , Gertz, Morie A. , Wechalekar, Ashutosh D. , Hegenbart, Ute , Dispenzieri, Angela , Jaccard, Arnaud , Merlini, Giampaolo , Dimopoulos, Meletios A , Schönland, Stefan , Klersy, Catherine , Kastritis, Efstathios , Palladini, Giovanni

Mayo Clinic

Journal of Clinical Oncology | October 23, 2012 | Volume: 30 | Issue: 36 | Pages: 4541-4549

10.1200/jco.2011.37.7614 | PMID 23091105 Get It

Purpose To identify the criteria for hematologic and cardiac response to treatment in immunoglobulin light chain (AL) amyloidosis based on survival analysis of a large patient population. Patients and Methods We gathered for analysis 816 patients with AL amyloidosis from seven referral centers in the European Union and the United States. A different cohort of 374 patients prospectively evaluated at the Pavia Amyloidosis Research and Treatment Center was used for validation. Data was available for all patients before and 3 and/or 6 months after initiation of first-line therapy. The prognostic relevance of different criteria for hematologic and cardiac response was assessed. Results There was a strong correlation between the extent of reduction of amyloidogenic free light chains (FLCs) and improvement in survival. This allowed the identification of four levels of response: amyloid complete response (normal FLC ratio and negative serum and urine immunofixation), very good partial response (difference between involved and uninvolved FLCs [dFLC] < 40 mg/L), partial response (dFLC decrease > 50%), and no response. Cardiac involvement is the major determinant of survival, and changes in cardiac function after therapy can be reliably assessed using the cardiac biomarker N-terminal natriuretic peptide type B (NT-proBNP). Changes in FLC and NT-proBNP predicted survival as early as 3 months after treatment initiation. Conclusion This study identifies and validates new criteria for response to first-line treatment in AL amyloidosis, based on their association with survival in large patient populations, and offers surrogate end points for clinical trials.
Faculty Opinions recommendation of Large refractory colonic polyps: is it time to change our practice? A prospective study of the clinical and economic impact of a tertiary referral colonic mucosal resection and polypectomy service (with videos).
Chua, Heidi K

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 17, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1165025.625902 Get It

Effect of a neurohospitalist service on outcomes at an academic medical center
Douglas, Vanja C. , Berg, Geraldine, Freeman, William D. , Josephson, S. Andrew , Scott, Brian J. , Freeman, William D

Mayo Clinic

Neurology | August 23, 2012 | Volume: 79 | Issue: 10 | Pages: 988-994

10.1212/wnl.0b013e31826846cb | PMID 22914833 Get It

Abstract 2930: Novel colorectal cancer loci in multiplex-proficient mismatch repair families
Cunningham, Julie M. , Cicek, Mine , Brooke, Fridley, Serie, Daniel, Diergaarde, Brenda , Kontriris, Theodore, Younghusband, Ban, Gallinger, Steven, Jenkins, Mark A. , Templeton, Allyson , Green, Roger, Parry, Susan, Young, Joanne , Thomas, Duncan C. , Lindor, Noralane M. , Thibodeau, Stephen N. , Goode, Ellen L. , CFR., Colon, Bamlet, William R. , Haile, Robert W. , Marchand, Loı̈c Le , Newcomb, Polly A. , Hopper, John L. , Casey, Graham , Schumacher, Fredrick R. , Chen, Zhu , Winship, Ingrid , Macrae, Finlay , Young, Graeme P. , Buchanan, Daniel D. , Bishop, D. Timothy , Potter, John D. , CFR., Colon, Jenkins, Mark A , Diergaarde, Brenda

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2930-2930

10.1158/1538-7445.am2012-2930 Get It

Abstract A substantial proportion of familial colorectal cancer (CRC) is not a consequence of known susceptibility loci, such as mismatch repair (MMR) genes, supporting the existence of additional loci. To identify novel CRC loci, we conducted a genome-wide linkage scan in 356 white families with no evidence of defective MMR (i.e., no tumors with loss of expression of MMR proteins; no microsatellite instability (MSI)-high tumors, and no evidence of linkage to MMR genes). This represents the largest linkage analysis of proficient MMR (pMMR) familial CRC to date. Families were ascertained via the NCI-supported Colon Cancer Family Registry multi-site (Colon CFR) consortium, the City of Hope, and Memorial University of Newfoundland. A total of 1,612 individuals (average 5.0 per family, range 2-10 with an average of 2.2 affected and 2.8 unaffected individuals) were genotyped using genome-wide single nucleotide polymorphism linkage arrays; parametric and non-parametric linkage analysis used MERLIN in a priori-defined family groups. Five lod scores greater than 3.0 were observed, accounting for heterogeneity, in four chromosomal regions. The greatest lod scores were at 4q21.1 among families with mean age of diagnosis less than 50 years (dominant HLOD=4.51, α=0.84, 145.40 cM, rs10518142) and at 12q24.32 among all families (dominant HLOD=3.60, α=0.48, 285.15 cM, rs952093). Among families with four or more affected individuals and among clinic-based families, a common peak was observed at 15q22.31 (101.40 cM, rs1477798; dominant HLOD=3.07, α=0.29; dominant HLOD=3.03, α=0.32, respectively). Analysis of families with only two affected individuals yielded a peak at 8q13.2 (recessive HLOD=3.02, α=0.51, 132.52 cM, rs1319036). These linkage regions comprise previously unreported loci, supporting the hypothesis that novel loci contribute to CRC in familial pMMR cases. These loci are also largely distinct from those identified in case-control GWAS. To follow up on these findings, a custom Agilent Sure Select Target Enrichment panel has been designed for genes in three of these regions, in order to sequence probands using an Illumina HiSeq 2000. This study demonstrates the utility of family-based data and provides evidence for additional alleles for familial CRC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2930. doi:1538-7445.AM2012-2930